Abstracts tagged "Japanese and rheumatoid arthritis (RA)"

Abstract Number: 1324 • 2012 ACR/ARHP Annual Meeting
Golimumab, A Human Anti-TNF Monoclonal Antibody, Administered Subcutaneously Every Four Weeks As Monotherapy in Patients with Active Rheumatoid Arthritis Despite Disease Modifying Antirheumatic Drug Therapy: Week 104 Results of Clinical, Radiographic and Safety Assessments
Tsutomu Takeuchi¹, Masayoshi Harigai², Yoshiya Tanaka³, Hisashi Yamanaka⁴, Naoki Ishiguro⁵, Kazuhiko Yamamoto⁶, Minoru Kanazawa⁷, Yoshinori Murakami⁸, Toru Yoshinari⁹, Daniel Baker¹⁰, Nobuyuki Miyasaka¹¹ and Takao Koike¹², ¹Keio University School of Medicine, Tokyo, Japan, ²Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, ³The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁴Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Department of Orthopedic Surgery, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan, ⁶Department of Allergy & Rheumatology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, ⁷Director of Respiratory Center Professor of Respiratory, Medicine Saitama Medical University, Moroyama, Iruma-Gun, Saimata, Japan, ⁸Medical writing, Janssen Pharmaceutical KK, Tokyo, Japan, ⁹2-6-18, Kitahama, Chuo-ku, Mitsubishi Tanabe Pharma Corporation, Osaka, Japan, ¹⁰Janssen Research & Development, LLC., Spring House, PA, ¹¹Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan, ¹²Sapporo medical center NTT EC, Sapporo, Japan
Golimumab, A Human Anti-TNF Monoclonal Antibody, Administered Subcutaneously Every Four Weeks as Monotherapy in Patients with Active Rheumatoid Arthritis Despite Disease Modifying Antirheumatic Drug Therapy:…
Abstract Number: 1325 • 2012 ACR/ARHP Annual Meeting
Prevention of Joint Destruction in Patients with High Disease Activity or High C-Reactive Protein
Yoshiya Tanaka¹, Masayoshi Harigai², Tsutomu Takeuchi³, Hisashi Yamanaka⁴, Naoki Ishiguro⁵, Kazuhiko Yamamoto⁶, Yutaka Ishii⁷, Daniel Baker⁸, Nobuyuki Miyasaka⁹ and Takao Koike¹⁰, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, ³Keio University School of Medicine, Tokyo, Japan, ⁴Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Department of Orthopedic Surgery, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan, ⁶Department of Allergy & Rheumatology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, ⁷Medical Affaires, Janssen Pharmaceutical K.K, Tokyo, Japan, ⁸Janssen Research & Development, LLC., Spring House, PA, ⁹Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan, ¹⁰Sapporo medical center NTT EC, Sapporo, Japan
Prevention of Joint Destruction in Patients with High Disease Activity or High C-reactive proteinBackground/Purpose: In Japan, 2 doses (50mg and 100mg) of golimumab (GLM) were…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].